- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03649113
Percutaneous Sclerotherapy of Symptomatic Liver Hemangioma With Bleomycin (Hemangioma)
Study Overview
Detailed Description
Twenty-five patients with symptomatic liver hemangioma will be enrolled after an informed consent being obtained. Patients' symptoms related to liver mass, including the pain severity being measured by visual analogue scale, discomfort, early satiety, or nausea will be recorded. Liver function tests, coagulation tests, and complete blood count will be checked before the intervention. A triple phase abdominal CT scan with the administration of intravenous contrast medium will also be performed before the procedure. Exclusion criteria include hepatic or renal impairment, abdominal symptoms unrelated to a liver mass, uncorrectable coagulopathy, lung fibrosis, allergy to contrast media, systemic infection, liver abscess, and biliary obstruction.
Patients will be sufficiently hydrated with normal saline before the procedure. Corticosteroid and prophylactic antibiotics will be administered before the procedure. Antibiotics will be continued for 3 days after the procedure.
The liver mass will be punctured under guidance of ultrasonography with a 20- or 22-gauge Chiba needle. Contrast medium will be injected under fluoroscopy guidance to assess any possible communication with the biliary tree and to evaluate the amount of sclerosing agent which could be safely injected. Then, the mixture of Bleomycin (Bleocin-S; Korea United Pharm Inc., South Korea) and Lipiodol (Ultra-Fluid, Guerbet, France) will be slowly injected under continuous guidance of fluoroscopy. No more than 45 units of Bleomycin and 15 cc of Lipiodol will be injected in a single session.
Any complication taking place during and within 30 days after the procedure will be recorded. Liver function tests, coagulation tests, and complete blood count will be repeated the day after the procedure, and 6 months after the procedure. Also, a triple phase abdominal CT scan will be repeated in 6 months, and 12 months after the intervention. The patients' symptoms will be asked by phone after 12 months. The changes in lesion size on CT scan and in patients' symptoms will be evaluated.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Tehran, Iran, Islamic Republic of, 1419733141
- Imam Khomeini Hospital Complex, Tehran University of Medical Sciences
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- patients with symptomatic liver hemangioma
Exclusion Criteria:
- hepatic or renal impairment
- abdominal symptoms unrelated to a liver mass
- uncorrectable coagulopathy
- lung fibrosis
- allergy to contrast media
- systemic infection
- liver abscess
- biliary obstruction
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: sclerotherapy arm
Patients with symptomatic liver hemangioma undergoing sclerotherapy (percutaneous injection) with 45 units of Bleomycin once during the procedure
|
The liver mass will be punctured under guidance of ultrasonography with a 20- or 22-gauge Chiba needle.
Contrast medium will be injected under fluoroscopy guidance to assess any possible communication with the biliary tree and to evaluate the amount of sclerosing agent which could be safely injected.
Then, the mixture of Bleomycin (Bleocin-S; Korea United Pharm Inc., South Korea) and Lipiodol (Ultra-Fluid, Guerbet, France) will be slowly injected under continuous guidance of fluoroscopy.
No more than 45 units of Bleomycin and 15 cc of Lipiodol will be injected in a single session.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in patient satisfaction assessed by the Visual Analog Scale (VAS) after 6 months
Time Frame: 6 months
|
Pain is subjectively assessed based on a visual analog scale (VAS) before and 6 months after intervention. Change in VAS is recorded. VAS is between zero (no pain at all) and 10 (worst pain imaginable). |
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of major adverse events
Time Frame: During the procedure and within 30 days after the procedure
|
Incidence of major adverse events that may cause any of the following: A) Require therapy, minor hospitalization (less than 48 hours) B) Require major therapy, unplanned increase in level of care, prolonged hospitalization (more than 48 hours) C) Permanent adverse sequel D) Death
|
During the procedure and within 30 days after the procedure
|
Change in hemangioma size
Time Frame: 6 months
|
The size of the hemangioma is assessed on CT scans performed before and 6 months after the procedure.
The largest diameter of the hemangioma is measured on axial images.
|
6 months
|
Collaborators and Investigators
Investigators
- Study Chair: Hadi Rokni Yazdi, MD, Tehran University of Medical Sciences, tehran, iran
Publications and helpful links
General Publications
- Ayoobi Yazdi N, Dashti H, Batavani N, Borhani A, Shakiba M, Rokni Yazdi H. Percutaneous Sclerotherapy for Giant Symptomatic Liver Hemangiomas: A Pilot Study. J Vasc Interv Radiol. 2018 Feb;29(2):233-236. doi: 10.1016/j.jvir.2017.10.009.
- van der Vleuten CJ, Kater A, Wijnen MH, Schultze Kool LJ, Rovers MM. Effectiveness of sclerotherapy, surgery, and laser therapy in patients with venous malformations: a systematic review. Cardiovasc Intervent Radiol. 2014 Aug;37(4):977-89. doi: 10.1007/s00270-013-0764-2. Epub 2013 Nov 7.
- Negrier C, Delmas MC, Ranchin B, Cochat P, Dechavanne M. Decreased factor XII activity in a child with nephrotic syndrome and thromboembolic complications. Thromb Haemost. 1991 Oct 1;66(4):512-3. No abstract available.
- Blaise S, Charavin-Cocuzza M, Riom H, Brix M, Seinturier C, Diamand JM, Gachet G, Carpentier PH. Treatment of low-flow vascular malformations by ultrasound-guided sclerotherapy with polidocanol foam: 24 cases and literature review. Eur J Vasc Endovasc Surg. 2011 Mar;41(3):412-7. doi: 10.1016/j.ejvs.2010.10.009. Epub 2010 Dec 15.
- Mathur NN, Rana I, Bothra R, Dhawan R, Kathuria G, Pradhan T. Bleomycin sclerotherapy in congenital lymphatic and vascular malformations of head and neck. Int J Pediatr Otorhinolaryngol. 2005 Jan;69(1):75-80. doi: 10.1016/j.ijporl.2004.08.008.
- Vilgrain V, Boulos L, Vullierme MP, Denys A, Terris B, Menu Y. Imaging of atypical hemangiomas of the liver with pathologic correlation. Radiographics. 2000 Mar-Apr;20(2):379-97. doi: 10.1148/radiographics.20.2.g00mc01379.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Liver Hemangioma Sclerotherapy
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hemangioma Liver
-
Second Affiliated Hospital, School of Medicine,...Recruiting
-
The Second Affiliated Hospital of Chongqing Medical...RecruitingHepatectomy | Liver Cancer | Hepatolithiasis | Hepatic HemangiomaChina
-
Medical University of ViennaCompletedLiver Neoplasms | Liver Metastasis | Echinococcosis, Hepatic | Liver HemangiomaAustria
-
Université de SousseSahloul Hospital of SousseCompletedLiver Angioma
-
Southwest Hospital, ChinaCompletedLaparoscopic Hepatectomy | Liver | Radio-frequency Ablation | Giant Cavernous HemangiomasChina
-
Shanghai Children's Medical CenterNot yet recruitingHemangioendothelioma of LiverChina
-
Shuguo Zheng, MDUnknownLiver Diseases | Liver Neoplasms | Hepatic HaemangiomaChina
-
Peking Union Medical College HospitalUnknownHepatic Hemangioma Located in the Right Liver | Laparotomy SurgeryChina
-
Zhujiang HospitalUnknownInfantile Hemangioma | Capillary Hemangioma | Capillary Hemangiomas | Hemangioma, Capillary Infantile | Strawberry HemangiomaChina
Clinical Trials on sclerotherapy arm
-
Hospital Occidente de KennedyUniversidad El Bosque, BogotáCompleted
-
Nanjing Children's HospitalRecruiting
-
Maaynei Hayesha Medical CenterCompleted
-
Derzhavin Tambov State UniversityRecruiting
-
Helsinki University Central HospitalActive, not recruiting
-
The Second Hospital of Nanjing Medical UniversityRecruitingRectal Prolapse | Internal HemorrhoidChina
-
Maciej Stukan, MD, PhDUnknown
-
Oulu University HospitalHelsinki University Central HospitalRecruiting
-
Oulu University HospitalCompleted
-
Institute of Liver and Biliary Sciences, IndiaNot yet recruitingLiver Cirrhosis | Internal HemorrhoidIndia